Drug updated on 10/29/2024
| Dosage Form | Injection (intravenous: 20 mg/5 mL [4 mg/mL]) |
| Drug Class | CC chemokine receptor type 4 (CCR4)-directed monoclonal antibodies |
| Ongoing and Completed Studies | ClinicalTrials.gov |
Indication
- Indicated for the treatment of adult patients with relapsed or refractory mycosis fungoides or Szary syndrome after at least one prior systemic therapy.
Latest News
Summary
- This summary is based on the review of two systematic review(s)/meta-analysis(es). [1-2]
- The MAVORIC trial indicated that mogamulizumab (Poteligeo) demonstrated favorable outcomes in patients with mycosis fungoides (MF) and Sézary syndrome (SS) compared to vorinostat, although the trial's crossover design introduces uncertainty into these results.
- A systematic review of 20 randomized controlled trials (RCTs) showed a wide variability in effectiveness outcomes for various interventions in MF, with complete response (CR) rates ranging from 0% to 83% and objective response rates (ORR) from 0% to 88%.
- The evidence comparing mogamulizumab to treatments like methotrexate, bexarotene, and vorinostat was limited and of low certainty, mainly due to study design flaws and small sample sizes, emphasizing the need for caution in interpreting these comparisons.
- There is no safety information available in the reviewed studies.
- There is no population types or subgroups information available in the reviewed studies.
Product Monograph / Prescribing Information
| Document Title | Year | Source |
|---|---|---|
| Poteligeo (mogamulizumab-kpkc) Prescribing Information. | 2023 | Kyowa Kirin, Inc., Princeton, NJ |
Systematic Reviews / Meta-Analyses
| Document Title | Year | Source |
|---|---|---|
| Clinicopathological definition, management and prognostic value of mogamulizumab-associated rash and other cutaneous events: A systematic review | 2024 | Journal of the European Academy of Dermatology and Venereology |
| Interventions for mycosis fungoides | 2020 | The Cochrane Database of Systematic Reviews |
Clinical Practice Guidelines
| Document Title | Year | Source |
|---|---|---|
| Mogamulizumab for Previously Treated Mycosis Fungoides and Sezary Syndrome: An Evidence Review Group Perspective of a NICE Single Technology Appraisal | 2022 | PharmacoEconomics |
| Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lymphoma. | 2020 | Journal for ImmunoTherapy of Cancer |